Latest & greatest articles for opioid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on opioid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on opioid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for opioid

61. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews.

Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews. BACKGROUND: Chronic pain is common and can be challenging to manage. Despite increased utilisation of opioids, the safety and efficacy of long-term use of these compounds for chronic non-cancer pain (CNCP) remains controversial. This overview of Cochrane Reviews complements the overview entitled 'High-dose opioids for chronic non-cancer pain: an overview of Cochrane (...) Reviews'. OBJECTIVES: To provide an overview of the occurrence and nature of adverse events associated with any opioid agent (any dose, frequency, or route of administration) used on a medium- or long-term basis for the treatment of CNCP in adults. METHODS: We searched the Cochrane Database of Systematic Reviews (the Cochrane Library) Issue 3, 2017 on 8 March 2017 to identify all Cochrane Reviews of studies of medium- or long-term opioid use (2 weeks or more) for CNCP in adults aged 18 and over. We

Cochrane2017

62. High-dose opioids for chronic non-cancer pain: an overview of Cochrane Reviews.

High-dose opioids for chronic non-cancer pain: an overview of Cochrane Reviews. BACKGROUND: Chronic pain is typically described as pain on most days for at least three months. Chronic non-cancer pain (CNCP) is any chronic pain that is not due to a malignancy. Chronic non-cancer pain in adults is a common and complex clinical issue where opioids are routinely used for pain management. There are concerns that the use of high doses of opioids for chronic non-cancer pain lacks evidence (...) of effectiveness and may increase the risk of adverse events. OBJECTIVES: To describe the evidence from Cochrane Reviews and Overviews regarding the efficacy and safety of high-dose opioids (here defined as 200 mg morphine equivalent or more per day) for chronic non-cancer pain. METHODS: We identified Cochrane Reviews and Overviews through a search of the Cochrane Database of Systematic Reviews (The Cochrane Library). The date of the last search was 18 April 2017. Two review authors independently assessed

Cochrane2017

63. CORRIGENDUM FOR “Effects of Opioid Antagonism on Melanocortin Peptides and Cortisol Levels in Human Cerebrospinal Fluid”

CORRIGENDUM FOR “Effects of Opioid Antagonism on Melanocortin Peptides and Cortisol Levels in Human Cerebrospinal Fluid” 29266110 2017 12 24 2472-1972 1 11 2017 Nov 01 Journal of the Endocrine Society J Endocr Soc CORRIGENDUM FOR "Effects of Opioid Antagonism on Melanocortin Peptides and Cortisol Levels in Human Cerebrospinal Fluid". 1331 10.1210/js.2017-00381 [This corrects the article DOI: 10.1210/js.2017-00289.]. eng Published Erratum 2017 10 05 United States J Endocr Soc 101697997 2472

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

64. The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery

The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery 28806217 2017 08 14 2017 08 18 1532-8651 42 5 2017 Sep/Oct Regional anesthesia and pain medicine Reg Anesth Pain Med The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery. 669-673 10.1097/AAP.0000000000000642 Multiple animal studies suggest that ondansetron ameliorates opioid-induced hyperalgesia and tolerance (...) . In this study, we aimed to determine if the administration of ondansetron prior to spinal anesthesia would have an effect on intrathecal opioid-induced acute opioid tolerance, postoperative pain, and analgesic requirements in patients undergoing cesarean delivery with spinal anesthesia. Eighty-six patients undergoing elective cesarean delivery were recruited and randomly allocated to receive either 8 mg intravenous ondansetron (n = 44) or placebo (n = 42) in a prospective, double-blind design. All patients

EvidenceUpdates2017

65. Local Infiltration Analgesia With Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use After Total Knee Arthroplasty: Results of a Randomized Controlled Trial

Local Infiltration Analgesia With Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use After Total Knee Arthroplasty: Results of a Randomized Controlled Trial 28802777 2017 08 13 2017 08 27 1532-8406 2017 Jul 25 The Journal of arthroplasty J Arthroplasty Local Infiltration Analgesia With Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use After Total Knee Arthroplasty: Results of a Randomized Controlled Trial. S0883-5403(17)30640-X 10.1016/j.arth.2017.07.024 Local (...) infiltration analgesia (LIA) with liposomal bupivacaine (LB) in patients undergoing total knee arthroplasty (TKA) has yielded mixed results. The PILLAR study, which was designed to minimize limitations associated with previous studies, compared the effects of LIA with or without LB on pain scores, opioid consumption, including proportion of opioid-free patients, time to first opioid rescue, and safety after primary unilateral TKA. Patients (N = 140) were randomized to LIA with LB 266 mg/20 mL (admixed

EvidenceUpdates2017

66. Naloxegol (Moventig) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation

Naloxegol (Moventig) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation Prescrire IN ENGLISH - Spotlight ''Naloxegol (Moventig°) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation'', 1 October 2017 {1} {1} {1} | | > > > Naloxegol (Moventig°) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Naloxegol (Moventig°) and opioid-induced constipation. Its abdominal adverse effects are probably as troublesome as constipation FEATURED REVIEW Naloxegol tablets have been authorised in the European Union for adults with troublesome opioid-induced constipation despite laxative therapy. Does naloxegol relieve discomfort in these patients? What

Prescrire2017

67. HIV and Chronic Pain, Part 2: Addressing the Opioid Public Health Crisis

HIV and Chronic Pain, Part 2: Addressing the Opioid Public Health Crisis 29662723 2018 11 14 2168-3808 35 4 2017 Oct Rehabilitation oncology (American Physical Therapy Association. Oncology Section) Rehabil Oncol HIV and Chronic Pain, Part 2: Addressing the Opioid Public Health Crisis. 197-198 Pullen Sara D SD Emory University School of Medicine, Department of Rehabilitation Medicine, Atlanta, GA 30322. eng P30 AI050409 AI NIAID NIH HHS United States Journal Article United States Rehabil Oncol

Rehabilitation oncology (American Physical Therapy Association. Oncology Section)2017 Full Text: Link to full Text with Trip Pro

68. Contribution of Opioid-Involved Poisoning to the Change in Life Expectancy in the United States, 2000-2015

Contribution of Opioid-Involved Poisoning to the Change in Life Expectancy in the United States, 2000-2015 28975295 2017 10 16 2018 11 13 1538-3598 318 11 2017 09 19 JAMA JAMA Contribution of Opioid-Involved Poisoning to the Change in Life Expectancy in the United States, 2000-2015. 1065-1067 10.1001/jama.2017.9308 Dowell Deborah D National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. Arias Elizabeth E National Center for Health (...) Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. Baldwin Grant G National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. eng Journal Article United States JAMA 7501160 0098-7484 0 Analgesics, Opioid AIM IM MMWR Morb Mortal Wkly Rep. 2015 Jan 9;63(53):1238-42 25577989 NCHS Data Brief. 2016 Jun;(250):1-8 27308863 Lancet. 2017 Apr 1;389(10076):1323-1335 28236464 MMWR Morb Mortal Wkly Rep. 2016 Jan 01;64(50-51):1378

JAMA2017 Full Text: Link to full Text with Trip Pro

69. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. BACKGROUND: Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugsNeedle syringe programmes (NSP) and opioid substitution therapy (OST) are the primary interventions to reduce hepatitis C (HCV) transmission in people who inject drugs. There is good evidence for the effectiveness of NSP and OST (...) in reducing injecting risk behaviour and increasing evidence for the effectiveness of OST and NSP in reducing HIV acquisition risk, but the evidence on the effectiveness of NSP and OST for preventing HCV acquisition is weak. OBJECTIVES: To assess the effects of needle syringe programmes and opioid substitution therapy, alone or in combination, for preventing acquisition of HCV in people who inject drugs. SEARCH METHODS: We searched the Cochrane Drug and Alcohol Register, CENTRAL, the Cochrane Database

Cochrane2017

70. Distribution of prescription opioid use among privately insured cancer-free adults: US, 2001–2013

Distribution of prescription opioid use among privately insured cancer-free adults: US, 2001–2013 28892817 2018 01 04 2018 11 13 1539-3704 167 9 2017 11 07 Annals of internal medicine Ann. Intern. Med. Distribution of Prescription Opioid Use Among Privately Insured Adults Without Cancer: United States, 2001 to 2013. 684-686 10.7326/M17-1408 Sun Eric C EC From Stanford University, Stanford, California, and Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts. Jena (...) Anupam B AB From Stanford University, Stanford, California, and Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts. eng DP5 OD017897 OD NIH HHS United States K08 DA042314 DA NIDA NIH HHS United States Journal Article Research Support, N.I.H., Extramural 2017 09 12 United States Ann Intern Med 0372351 0003-4819 0 Analgesics, Opioid AIM IM Am J Epidemiol. 2011 Mar 15;173(6):676-82 21330339 Stat J IAOS. 2012;28(1-2):43-51 26146526 Pharmacoepidemiol Drug Saf. 2006 Sep;15(9

Annals of Internal Medicine2017 Full Text: Link to full Text with Trip Pro

71. Emerging Non-Opioid Drugs for the Treatment of Pain

Emerging Non-Opioid Drugs for the Treatment of Pain Emerging Non-Opioid Drugs for the Treatment of Pain | CADTH.ca Find the information you need Emerging Non-Opioid Drugs for the Treatment of Pain Emerging Non-Opioid Drugs for the Treatment of Pain Published on: September 11, 2017 Project Number: ES0322-000 Product Line: Result type: Report Opioids are used extensively in the treatment of pain. Even with the growing awareness about the risks associated with opioids and the recognition (...) of the current opioid crisis, the number of prescriptions for opioids is still rising in Canada. Safe and effective pharmacological alternatives to opioids could have a significant impact on the opioid crisis and the management of pain in Canada. Currently, several non-opioid drugs are used for the treatment of pain, such as acetaminophen, NSAIDs, corticosteroids, antidepressants, anticonvulsants, and others. However, these drugs have not been able to completely replace opioids in the treatment of pain

Canadian Agency for Drugs and Technologies in Health - Environmental Scanning2017

72. Personal Protective Equipment for Health Care Workers Exposed to Opioids: Clinical Effectiveness and Guidelines

Personal Protective Equipment for Health Care Workers Exposed to Opioids: Clinical Effectiveness and Guidelines Personal Protective Equipment for Health Care Workers Exposed to Opioids: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Personal Protective Equipment for Health Care Workers Exposed to Opioids: Clinical Effectiveness and Guidelines Personal Protective Equipment for Health Care Workers Exposed to Opioids: Clinical Effectiveness and Guidelines Published (...) on: September 8, 2017 Project Number: RA0926-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness on the use of personal protective equipment for health care workers working with patients who have used opioids? What are the evidence-based guidelines regarding the use of personal protective equipment for health care workers working with patients who have used opioids? Key Message No relevant literature was identified

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

73. Pupillometry-guided Intraoperative Remifentanil Administration versus Standard Practice Influences Opioid Use: A Randomized Study

Pupillometry-guided Intraoperative Remifentanil Administration versus Standard Practice Influences Opioid Use: A Randomized Study 28719527 2017 07 18 2017 08 09 2017 08 09 1528-1175 127 2 2017 Aug Anesthesiology Anesthesiology Pupillometry-guided Intraoperative Remifentanil Administration versus Standard Practice Influences Opioid Use: A Randomized Study. 284-292 10.1097/ALN.0000000000001705 Pupillometry has shown promising results for assessing nociception in anesthetized patients. However (...) , its benefits in clinical practice are not demonstrated. The aim of this prospective randomized study was to evaluate the impact of intraoperative pupillometry monitoring on perioperative opioid consumption in major gynecologic surgery. After receiving ethics committee approval and written consent of patients, American Society of Anesthesiologists status I to II women undergoing gynecologic surgery were included in this single-blinded, prospective, parallel-arm randomized study. General anesthesia

EvidenceUpdates2017

75. Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder

Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder | CADTH.ca CADTH Document Viewer Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder Table of Contents Search this document Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder August 2017 Summary Vivitrol is an extended-release injectable formulation of naltrexone, administered as an intramuscular injection once a month (...) . Naltrexone is an opioid-receptor antagonist that blocks the euphoric effects of opioids. Unlike other treatments for opioid use disorder, including buprenorphine/naloxone and methadone, naltrexone is not associated with the development of tolerance and dependence, and lacks the potential for misuse and diversion. However, because the oral formulation requires a daily dosage, poor adherence to the medication has limited its efficacy for the prevention of relapse in patients with opioid use disorder

CADTH - Issues in Emerging Health Technologies2017

76. Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder

Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder | CADTH.ca CADTH Document Viewer Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder Table of Contents Search this document Injectable Extended-Release Naltrexone to Treat Opioid Use Disorder August 2017 Summary Vivitrol is an extended-release injectable formulation of naltrexone, administered as an intramuscular injection once a month (...) . Naltrexone is an opioid-receptor antagonist that blocks the euphoric effects of opioids. Unlike other treatments for opioid use disorder, including buprenorphine/naloxone and methadone, naltrexone is not associated with the development of tolerance and dependence, and lacks the potential for misuse and diversion. However, because the oral formulation requires a daily dosage, poor adherence to the medication has limited its efficacy for the prevention of relapse in patients with opioid use disorder

CADTH - Issues in Emerging Health Technologies2017

77. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study.

Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. Objectives To assess the impact of in utero co-exposure to psychotropic medications and opioids on the incidence and severity of neonatal drug withdrawal. Design Observational cohort study. Setting Nationwide sample of pregnancies in publicly insured women in the US, nested in the Medicaid Analytic eXtract (2000-10). Participants 201 275 pregnant women with public insurance who (...) were exposed to opioids around the time of delivery and their liveborn infants. Interventions In utero exposure to psychotropic medications, in particular antidepressants, atypical antipsychotics, benzodiazepines, gabapentin, and non-benzodiazepine hypnotics (Z drugs), with prescriptions filled within the same time window as prescriptions for opioids. Main outcome measure Diagnosis of neonatal drug withdrawal in infants exposed in utero to opioids and psychotropic medications compared with opioids

BMJ2017

78. Improving Adherence to Long-term Opioid Therapy Guidelines to Reduce Opioid Misuse in Primary Care: A Cluster-Randomized Clinical Trial

Improving Adherence to Long-term Opioid Therapy Guidelines to Reduce Opioid Misuse in Primary Care: A Cluster-Randomized Clinical Trial 28715535 2017 07 17 2017 07 17 2168-6114 2017 Jul 17 JAMA internal medicine JAMA Intern Med Improving Adherence to Long-term Opioid Therapy Guidelines to Reduce Opioid Misuse in Primary Care: A Cluster-Randomized Clinical Trial. 10.1001/jamainternmed.2017.2468 Prescription opioid misuse is a national crisis. Few interventions have improved adherence to opioid (...) -prescribing guidelines. To determine whether a multicomponent intervention, Transforming Opioid Prescribing in Primary Care (TOPCARE; http://mytopcare.org/), improves guideline adherence while decreasing opioid misuse risk. Cluster-randomized clinical trial among 53 primary care clinicians (PCCs) and their 985 patients receiving long-term opioid therapy for pain. The study was conducted from January 2014 to March 2016 in 4 safety-net primary care practices. Intervention PCCs received nurse care management

EvidenceUpdates2017

79. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health.

Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. Background: Despite the continuing epidemic of opioid misuse, data on the prevalence of prescription opioid use, misuse, and use disorders are limited. Objective: To estimate the prevalence of prescription opioid use, misuse, and use disorders and motivations for misuse among U.S. adults. Design: Survey. Setting: The 2015 National Survey on Drug Use and Health (NSDUH). Participants (...) : 72 600 eligible civilian, noninstitutionalized adults were selected for NSDUH, and 51 200 completed the survey interview. Measurements: Prescription opioid use, misuse, and use disorders. Results: Weighted NSDUH estimates suggested that, in 2015, 91.8 million (37.8%) U.S. civilian, noninstitutionalized adults used prescription opioids; 11.5 million (4.7%) misused them; and 1.9 million (0.8%) had a use disorder. Among adults with prescription opioid use, 12.5% reported misuse; of these, 16.7

Annals of Internal Medicine2017

80. Buprenorphine Formulations for the Treatment of Opioid Use Disorders: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines

Buprenorphine Formulations for the Treatment of Opioid Use Disorders: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines Buprenorphine Formulations for the Treatment of Opioid Use Disorders: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Buprenorphine Formulations for the Treatment of Opioid Use Disorders: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines (...) Buprenorphine Formulations for the Treatment of Opioid Use Disorders: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines Published on: July 31, 2017 Project Number: RC0908-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of various buprenorphine or buprenorphine-naloxone formulations for the treatment of opioid use disorders? What is the cost-effectiveness of various

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017